SCHEMBL4461599

SCHEMBL4461599

c1cc(N2CCCC2)ccc1C1CCOCC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.50
KCNH2 Q12809 1/20 0.50
L3MBTL1 Q9Y468 2/20 0.46
L3MBTL3 Q96JM7 2/20 0.46
SMN1; SMN2 Q16637 3/20 0.44
ALDH1A1 P00352 5/20 0.42
MAPT P10636 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
KDM4E B2RXH2 2/20 0.42
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
USP2 O75604 1/20 0.42
TP53 P04637 1/20 0.42
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
THRB P10828 1/20 0.42
ALOX15 P16050 1/20 0.42
HTT P42858 1/20 0.42
RECQL P46063 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30700722 0.96 HRH3 (0.47) HRH3KCNH2L3MBTL1L3MBTL3SMN1; SMN2
Hydrochloric Acid SCHEMBL31308866 0.94 HRH3 (0.46) HRH3KCNH2L3MBTL1L3MBTL3SMN1; SMN2
SCHEMBL4480849 0.91 HRH3 (0.43) HRH3KCNH2L3MBTL1L3MBTL3SMN1; SMN2
SCHEMBL4470001 0.91 HRH3 (0.43) HRH3KCNH2L3MBTL1L3MBTL3SMN1; SMN2
SCHEMBL5165447 0.90 ALDH1A1 (0.50) HRH3KCNH2SMN1; SMN2ALDH1A1MAPT
SCHEMBL23064493 0.88 L3MBTL1 (0.52) HRH3L3MBTL1L3MBTL3SMN1; SMN2ALDH1A1
SCHEMBL30228474 0.86 ALDH1A1 (0.52) L3MBTL1L3MBTL3SMN1; SMN2ALDH1A1MAPT
SCHEMBL28247589 0.84 ALDH1A1 (0.52) HRH3KCNH2L3MBTL1L3MBTL3SMN1; SMN2
SCHEMBL615270 0.80 L3MBTL1 (0.43) HRH3KCNH2L3MBTL1L3MBTL3SMN1; SMN2
SCHEMBL1673550 0.79 SIGMAR1 (0.52) L3MBTL1L3MBTL3SMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853243-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2014-10-07 US disclosed
US-7491724-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2009-02-17 US disclosed
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases MMP25, MMP2, MMP14 HRH3 299/4885KCNH2 4625/4885L3MBTL1 3117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.